As Biotechnology companies, Sesen Bio Inc. (NASDAQ:SESN) and BioTime Inc. (:) are our subject to contrast. And more specifically their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 shows Sesen Bio Inc. and BioTime Inc.s return on assets, return on equity and net margins.

Volatility & Risk

Sesen Bio Inc. has a beta of 0.65 and its 35.00% less volatile than S&P 500. From a competition point of view, BioTime Inc. has a 2.81 beta which is 181.00% more volatile compared to S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of Sesen Bio Inc. are 6.4 and 6.4. Competitively, BioTime Inc. has 3.5 and 3.5 for Current and Quick Ratio. Sesen Bio Inc.s better ability to pay short and long-term obligations than BioTime Inc.

Institutional and Insider Ownership

Institutional investors held 31.6% of Sesen Bio Inc. shares and 43.7% of BioTime Inc. shares. 6.56% are Sesen Bio Inc.s share held by insiders. Insiders Competitively, held 3.9% of BioTime Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Sesen Bio Inc. has -13.38% weaker performance while BioTime Inc. has 20.48% stronger performance.

Summary

BioTime Inc. beats on 5 of the 9 factors Sesen Bio Inc.

Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Continue reading here:
Sesen Bio Inc. (SESN) and BioTime Inc. (:) Contrasting side by side - FinanceMercury